Biotech’s excesses trouble investors

Cover image designed by Allison Brown for VCJ, based on Ja_inter/iStock/Getty Images; vectortatu/iStock/Getty Images; and alla_snesar/iStock/Getty Images.
Innovation stands at the core of the four-year-long biotech boom, and eager investors fall over themselves to get involved. Take Boston-based exosome-detection startup NanoView Biosciences. The company announced a $10 million Series B round in October, two years after taking ...

This content is available for Venture Capital subscribers only. Request a free trial to get access for a limited period

Venture Capital

Subscribe Now Request Trial

If you already have an active Venture Capital subscription, please sign in to view this article.